Edward J. Hennessy
Affiliations: | AstraZeneca, Boston, MA |
Google:
"Edward John Hennessy"Bio:
http://hdl.handle.net/1721.1/32521
Mean distance: 7.29 | S | N | B | C | P |
Parents
Sign in to add mentor| Stephen L. Buchwald | grad student | 2005 | MIT | |
| (The development and application of metal-catalyzed processes for organic synthesis) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Collie GW, Koh CM, O'Neill DJ, et al. (2019) Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors. Acs Medicinal Chemistry Letters. 10: 1322-1327 |
| Cidado J, Secrist JP, Gibbons FD, et al. (2018) Abstract 311: AZD4320 is a potent, dual Bcl-2/xLinhibitor that rapidly induces apoptosis in preclinical hematologic tumor models Cancer Research. 78: 311-311 |
| Hennessy EJ, Cornebise M, Gingipalli L, et al. (2017) Preparation of highly functionalized 1,5-disubstituted tetrazoles via palladium-catalyzed Suzuki coupling Tetrahedron Letters. 58: 1709-1713 |
| McCoull W, Hennessy EJ, Blades K, et al. (2016) Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors. Acs Medicinal Chemistry Letters. 7: 1118-1123 |
| Hennessy EJ, Chuaqui C, Ashton S, et al. (2016) Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. Acs Medicinal Chemistry Letters. 7: 514-519 |
| Hennessy EJ. (2016) Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity. Bioorganic & Medicinal Chemistry Letters |
| Hennessy EJ, Oza V, Adam A, et al. (2015) Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity. Journal of Medicinal Chemistry. 58: 7057-75 |
| Hird AW, Aquila BM, Hennessy EJ, et al. (2015) Small molecule inhibitor of apoptosis proteins antagonists: a patent review. Expert Opinion On Therapeutic Patents. 25: 755-74 |
| Hennessy EJ, Grewal G, Byth K, et al. (2015) Discovery of heterocyclic sulfonamides as sphingosine 1-phosphate receptor 1 (S1P1) antagonists. Bioorganic & Medicinal Chemistry Letters. 25: 2041-5 |
| Yang B, Lamb ML, Zhang T, et al. (2014) Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening. Journal of Medicinal Chemistry. 57: 9958-70 |